{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:56:19Z","timestamp":1792090579223,"version":"4.4.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Department of Health Systems, Management, and Policy, Colorado School of Public Health"},{"name":"University of Pittsburgh Health Resources and Services Administration Ruth L. Kirschstein National Research Service Award Primary Care Research Training Program","award":["T32 HP22240"],"award-info":[{"award-number":["T32 HP22240"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Childhood Obesity"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Inadequate care access may exacerbate the childhood obesity epidemic. Obesity treatments are recommended for adolescents, but the health-economic impacts of unequal treatment access are unclear. This study aims to evaluate the cost-effectiveness of improving access levels to adolescent obesity care and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this economic evaluation, we used a decision-analytic model to simulate a synthetic cohort of 1000 US adolescents from ages 12 to 26 on an annual basis. Modeled treatment strategies included phentermine-topiramate, semaglutide, bariatric surgery, and lifestyle modification (usual care). Primary analysis modeled perfect care access for reproducibility with prior studies. Secondary analyses modeled imperfect access to primary care visits, specialty visits, and treatment initiation among distinct groups by insurance coverage or race and ethnicity. Uncertainty analyses tested model parameter estimates. Outcomes were costs, health effects [averted obesity cases, quality-adjusted life years (QALYs)], and incremental cost-effectiveness ratios (ICERs) from health care sector and limited societal perspectives, including caregiver time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Phentermine-topiramate (vs. lifestyle) yielded an ICER of 2025 US$112,141\/QALY, and semaglutide (vs. phentermine-topiramate) yielded $166,513\/QALY under perfect access. Under imperfect access, cost-effectiveness and health gains were reduced. Cost-effectiveness was reduced by 11%, and averted obesity cases decreased from 57% to 3% for semaglutide. Health gains were lowest in Medicaid-insured, Black, or Hispanic youth. ICERs were sensitive to medication characteristics (costs, efficacy, discontinuation) and health utilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this economic evaluation, phentermine-topiramate and semaglutide were cost-effective under $200,000\/QALY, using 2025 pricing. Care access disparities limit health-economic gains for adolescents. Improving care access is critical to addressing the childhood obesity epidemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/21532176261454487","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:21:07Z","timestamp":1780482067000},"page":"379-388","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents"],"prefix":"10.1177","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8862-5707","authenticated-orcid":false,"given":"Tran T.","family":"Doan","sequence":"first","affiliation":[{"name":"Department of Health Systems, Management, and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heeseung J.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Health Outcomes Division, The University of Texas at Austin College of Pharmacy, Austin, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton L.V.","family":"Avance\u00f1a","sequence":"additional","affiliation":[{"name":"Health Outcomes Division, The University of Texas at Austin College of Pharmacy, Austin, Texas, USA."},{"name":"Department of Internal Medicine, The University of Texas at Austin Dell Medical School, Austin, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Peyyety","sequence":"additional","affiliation":[{"name":"Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan O.","family":"Bensignor","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Vajravelu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Center for Pediatric Research in Obesity and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"1.Centers for Disease Control and Prevention (CDC). Childhood Obesity Facts. Centers for Disease Control and Prevention; 2024. Available from: https:\/\/www.cdc.gov\/obesity\/childhood-obesity-facts\/childhood-obesity-facts.html [Last accessed: May5 2025]."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.11809"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-021-00442-0"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301806"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2023.2012"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247307"},{"issue":"2","key":"e_1_3_3_8_1","doi-asserted-by":"crossref","first-page":"e13535","DOI":"10.1111\/obr.13535","article-title":"Economic burden of childhood overweight and obesity: A systematic review and meta\u2010analysis","volume":"24","author":"Ling J","year":"2023","unstructured":"7.Ling J, , Chen S, , Zahry NR, , Kao TA. Economic burden of childhood overweight and obesity: A systematic review and meta\u2010analysis. Obes Rev 2023;24(2):e13535.","journal-title":"Obes Rev"},{"issue":"5","key":"e_1_3_3_9_1","first-page":"569","article-title":"Medications for obesity management: Effectiveness and value: A summary from the institute for clinical and economic review\u2019s new england comparative effectiveness public advisory council","volume":"29","author":"Atlas SJ","year":"2023","unstructured":"8.Atlas SJ, , Kim K, , Nhan E, et al. Medications for obesity management: Effectiveness and value: A summary from the institute for clinical and economic review\u2019s new england comparative effectiveness public advisory council. J Manag Care Spec Pharm 2023;29(5):569\u2013575.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"e2022060641","DOI":"10.1542\/peds.2022-060641","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl SE","year":"2023","unstructured":"9.Hampl SE, , Hassink SG, , Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 2023;151(2):e2022060641.","journal-title":"Pediatrics"},{"key":"e_1_3_3_11_1","unstructured":"10.The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. The White House; 2025. Available from: https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/11\/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients\/ [Last accessed: December28 2025]."},{"key":"e_1_3_3_12_1","unstructured":"11.Wingrove P Beasley D. US slashes 36% off Medicare spending on 15 high-priced medicines. Reuters. 2025. Available from: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/us-negotiated-medicare-prices-15-more-drugs-test-cost-savings-promise-2025-11-25\/"},{"key":"e_1_3_3_13_1","unstructured":"12.Novo Nordisk launches introductory self-pay offer for Wegovy and Ozempic for $199 per month. PR Newswire; 2025. Available from: https:\/\/www.prnewswire.com\/news-releases\/novo-nordisk-launches-introductory-self-pay-offer-for-wegovy-and-ozempic-for-199-per-month-302617100.html [Last accessed: November17 2025]."},{"key":"e_1_3_3_14_1","unstructured":"13.U.S. Department of Veterans Affairs. Office of Procurement Acquisition and Logistics. Federal Supply Schedule. Pharmaceutical Prices. 2025. Available from: https:\/\/www.fss.va.gov\/ [Last accessed: December28 2025]."},{"issue":"10","key":"e_1_3_3_15_1","doi-asserted-by":"crossref","first-page":"E2336400","DOI":"10.1001\/jamanetworkopen.2023.36400","article-title":"Cost-effectiveness of antiobesity drugs for adolescents with severe obesity","volume":"6","author":"Mital S","year":"2023","unstructured":"14.Mital S, , Nguyen HV. Cost-effectiveness of antiobesity drugs for adolescents with severe obesity. JAMA Netw Open 2023;6(10):E2336400.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.29178"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"16.Neumann P Sanders G Russell L Siegel J. Cost-effectiveness in health and medicine. 2016. Available from: https:\/\/global.oup.com\/academic\/product\/cost-effectiveness-in-health-and-medicine-9780190492939?cc=us&lang=en& [Last accessed: September23 2025].","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"issue":"4","key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"e230493","DOI":"10.1001\/jamahealthforum.2023.0493","article-title":"A prescription for achieving equitable access to antiobesity medications","volume":"4","author":"Wright DR","year":"2023","unstructured":"17.Wright DR, , Guo J, , Hernandez I. A prescription for achieving equitable access to antiobesity medications. JAMA Health Forum 2023;4(4):e230493.","journal-title":"JAMA Health Forum"},{"issue":"12","key":"e_1_3_3_19_1","doi-asserted-by":"crossref","first-page":"e13821","DOI":"10.1111\/obr.13821","article-title":"Addressing disparities: A systematic review of digital health equity for adolescent obesity prevention and management interventions","volume":"25","author":"Partridge SR","year":"2024","unstructured":"18.Partridge SR, , Knight A, , Todd A, et al. Addressing disparities: A systematic review of digital health equity for adolescent obesity prevention and management interventions. Obes Rev 2024;25(12):e13821.","journal-title":"Obes Rev"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2023.02.003"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2019.11.020"},{"issue":"10","key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamapediatrics.2025.2469","article-title":"Exploring challenges with widespread use of GLP-1\u2013based therapies for adolescents and young adults","volume":"179","author":"Luo J","year":"2025","unstructured":"21.Luo J, , Vajravelu ME, , Dusetzina SB. Exploring challenges with widespread use of GLP-1\u2013based therapies for adolescents and young adults. JAMA Pediatr 2025;179(10):1061\u20131063.","journal-title":"JAMA Pediatr"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acap.2024.04.003"},{"issue":"7","key":"e_1_3_3_24_1","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s11606-025-10012-y","article-title":"Medicaid coverage and prior authorization for antiobesity glucagon-like peptide-1 receptor agonists: A cross-sectional study of state policies","volume":"41","author":"Klebanoff MJ","year":"2026","unstructured":"23.Klebanoff MJ, , Chetty AK, , Doshi JA. Medicaid coverage and prior authorization for antiobesity glucagon-like peptide-1 receptor agonists: A cross-sectional study of state policies. J Gen Intern Med 2026;41(7):2003\u20132006.","journal-title":"J Gen Intern Med"},{"issue":"8","key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"e2329422","DOI":"10.1001\/jamanetworkopen.2023.29422","article-title":"Interpreting cost-effectiveness analyses of anti-obesity medications for the treatment of adolescent obesity\u2014reading the tea leaves","volume":"6","author":"Wright DR","year":"2023","unstructured":"24.Wright DR, , Luviano A, , Skelton JA. Interpreting cost-effectiveness analyses of anti-obesity medications for the treatment of adolescent obesity\u2014reading the tea leaves. JAMA Netw Open 2023;6(8):e2329422.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/23814683211061097"},{"issue":"6","key":"e_1_3_3_28_1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly AS","year":"2022","unstructured":"27.Kelly AS, , Bensignor MO, , Hsia DS, et al. Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid 2022;1(6)EVIDoa2200014.","journal-title":"NEJM Evid"},{"issue":"11","key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1007\/s11695-022-06265-9","article-title":"Trends in adolescent bariatric procedures: A 15-year analysis of the National Inpatient Survey","volume":"32","author":"Salimi-Jazi F","year":"2022","unstructured":"28.Salimi-Jazi F, , Chkhikvadze T, , Shi J, et al. Trends in adolescent bariatric procedures: A 15-year analysis of the National Inpatient Survey. Obes Surg 2022;32(11):3658\u20133665.","journal-title":"Obes Surg"},{"issue":"3","key":"e_1_3_3_30_1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1748-0361.2009.00238.x","article-title":"Comparison of program costs for parent\u2010only and family\u2010based interventions for pediatric obesity in medically underserved rural settings","volume":"25","author":"Janicke DM","year":"2009","unstructured":"29.Janicke DM, , Sallinen BJ, , Perri MG, et al. Comparison of program costs for parent\u2010only and family\u2010based interventions for pediatric obesity in medically underserved rural settings. J Rural Health 2009;25(3):326\u2013330.","journal-title":"J Rural Health"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198838197.001.0001"},{"issue":"9","key":"e_1_3_3_32_1","first-page":"626","article-title":"Patient adherence: A blind spot in cost-effectiveness analyses","volume":"15","author":"Rosen AB","year":"2009","unstructured":"31.Rosen AB, , Spaulding AB, , Greenberg D, et al. Patient adherence: A blind spot in cost-effectiveness analyses. Am J Manag Care 2009;15(9):626\u2013632.","journal-title":"Am J Manag Care"},{"issue":"1","key":"e_1_3_3_33_1","first-page":"1","article-title":"Weight regain following the cessation of GLP-1 RAs for weight management: A systematic review and meta-analysis","volume":"18","author":"West S","year":"2025","unstructured":"32.West S, , Scragg J, , Oke JL, et al. Weight regain following the cessation of GLP-1 RAs for weight management: A systematic review and meta-analysis. Obes Facts 2025;18(Suppl 1):1\u2013656.","journal-title":"Obes Facts"},{"key":"e_1_3_3_34_1","unstructured":"33.Wolters Kluwer. UpToDate. 2025. Available from: https:\/\/www.uptodate.com [Last accessed: December28 2025]."},{"issue":"2","key":"e_1_3_3_35_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamasurg.2016.3640","article-title":"Cost-effectiveness of bariatric surgery in adolescents with obesity","volume":"152","author":"Klebanoff MJ","year":"2017","unstructured":"34.Klebanoff MJ, , Chhatwal J, , Nudel JD, et al. Cost-effectiveness of bariatric surgery in adolescents with obesity. JAMA Surg 2017;152(2):136\u2013141.","journal-title":"JAMA Surg"},{"key":"e_1_3_3_36_1","unstructured":"35.U.S. Bureau of Economic Analysis. Gross Domestic Product: Implicit Price Deflator [GDPDEF]. FRED Federal Reserve Bank of St. Louis; 2023. Available from: https:\/\/fred.stlouisfed.org\/series\/GDPDEF [Last accessed: May31 2024]."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-017-3100-0"},{"issue":"3","key":"e_1_3_3_38_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol-a new facility for the measurement of health-related quality of life","volume":"16","author":"Group TE","year":"1990","unstructured":"37.Group TE. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy (New York) 1990;16(3):199\u2013208.","journal-title":"Health Policy (New York)"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208601"},{"issue":"4","key":"e_1_3_3_40_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MOP.0000000000001365","article-title":"Semaglutide for management of obesity in adolescents: Efficacy, safety, and considerations for clinical practice","volume":"36","author":"Bensignor MO","year":"2024","unstructured":"39.Bensignor MO, , Arslanian S, , Vajravelu ME. Semaglutide for management of obesity in adolescents: Efficacy, safety, and considerations for clinical practice. Curr Opin Pediatr 2024;36(4):449\u2013455.","journal-title":"Curr Opin Pediatr"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-024-03755-w"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5586"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-023-00813-9"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.010"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.2196\/69304"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00566-z"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2024.0351"},{"issue":"8","key":"e_1_3_3_48_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamapediatrics.2023.2018","article-title":"Current and future challenges regarding estimating costs to determine the value of interventions to manage unhealthy weight","volume":"177","author":"Luviano A","year":"2023","unstructured":"47.Luviano A, , Pandya A, , Wright DR. Current and future challenges regarding estimating costs to determine the value of interventions to manage unhealthy weight. JAMA Pediatr 2023;177(8):761\u2013763.","journal-title":"JAMA Pediatr"},{"issue":"8","key":"e_1_3_3_49_1","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/ijpo.13146","article-title":"Primary care perspectives on prescribing anti\u2010obesity medication for adolescents","volume":"19","author":"Chivate R","year":"2024","unstructured":"48.Chivate R, , Schoemer P, , Ragavan MI, et al. Primary care perspectives on prescribing anti\u2010obesity medication for adolescents. Pediatr Obes 2024;19(8):e13146.","journal-title":"Pediatr Obes"}],"container-title":["Childhood Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21532176261454487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21532176261454487","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21532176261454487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:16:34Z","timestamp":1785539794000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21532176261454487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.1177\/21532176261454487"],"URL":"https:\/\/doi.org\/10.1177\/21532176261454487","relation":{},"ISSN":["2153-2168","2153-2176"],"issn-type":[{"value":"2153-2168","type":"print"},{"value":"2153-2176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}